Reporting season scorecards and observations

By Tom Sartor

24 August 2020, 11:55 AM

August has been a story of cyclical and consumer-facing stocks in particular in terms of 1) surprising overly fearful expectations, and/or; 2) being well supported by the market even if they didn’t. Whether this can continue when fiscal support scales down will be a key question as we exit August.


Reporting Season Scorecard: A decent start

By Andrew Tang

17 August 2020, 3:20 PM

Reporting season kicked off in earnest last week with ~13% of the ASX 300 reporting results. The low bar for earnings was clearly evident with the bulk of companies reporting either inline or above (low) expectations despite median reported FY20 EPS growth coming in at -9%.


COVID-19: Pathway to a vaccine

By Derek Jellinek

23 July 2020, 2:50 PM

Executives from five drug companies leading the COVID-19 vaccine race (ie AstraZeneca (LON; AZN), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE)) appeared in front of the US House Energy and Commerce Oversight and Investigations Subcommittee to talk about their progress in developing a product the entire world desperately needs.


Asset Allocation: September quarter re-balance

By Tom Sartor

13 July 2020, 9:20 AM

The stunning rebound in the US equity market in the March quarter looks to have run ahead of fundamentals, particularly as the pandemic leaves complex economic questions in its wake. As such we remain on the look out to allocate more active weight toward beneficiaries of a cyclical recovery, but that looks far too early to call with the information at hand.

Results 1-10 of 58
  • Print this page
  • Copy Link